Ovide

Sneezing, Tracheitis, Emphysema + 43 more

Treatment

5 FDA approvals

20 Active Studies for Ovide

Treatment for

Sneezing

What is Ovide

Guaifenesin

The Generic name of this drug

Treatment Summary

Ethanol is a clear, colorless liquid that can be absorbed quickly by the body. It is used as an antiseptic and disinfectant, often in topical applications. It is also found in many pharmaceuticals and alcoholic beverages.

Goyescas 7 Syrups Original Cough and Cold

is the brand name

image of different drug pills on a surface

Ovide Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Goyescas 7 Syrups Original Cough and Cold

Guaifenesin

1958

497

Approved as Treatment by the FDA

Guaifenesin, also called Goyescas 7 Syrups Original Cough and Cold, is approved by the FDA for 5 uses which include Productive cough and induction of Productive cough .

Productive cough

induction of Productive cough

chest congestion

Phlegm

Coughing

Effectiveness

How Ovide Affects Patients

Alcohol causes cell damage by drying them out and destroying their inner structures. This makes it useful for killing bacteria and fungi. When alcohol is near nerves, it can lead to inflammation and nerve damage. Most of the ethanol that enters the body is broken down into harmless substances. Ethanol is used to dissolve certain drugs, as a mild sedative, and to bind to certain receptors in the body. It is also processed by the liver enzyme alcohol dehydrogenase.

How Ovide works in the body

Alcohol has a range of effects on the brain. It changes how neurons look, as well as the channels, enzymes, and receptors inside them. It also binds to the receptors for acetylcholine, serotonin, GABA, and glutamate. The calming effects of alcohol happen when it binds to GABA and glycine receptors. It also prevents the NMDA receptor from working properly. As an anti-infective, alcohol dehydrates cells by disrupting their osmotic balance.

When to interrupt dosage

The proposed dose of Ovide is contingent upon the diagnosed condition, such as Urinary Tract Infection (UTI), Hand Hygiene and ethylene glycol. The amount of dosage is contingent upon the technique of delivery (e.g. Topical or Solution, gel forming / drops) featured in the table below.

Condition

Dosage

Administration

Phlegm

20.0 mg/mL, , 100.0 mg/mL, 40.0 mg/mL, 200.0 mg/mL, 400.0 mg, 50.0 mg/mL, 200.0 mg, 600.0 mg, 225.0 mg/mL, 400.0 mg/mL, 300.0 mg/mL, 350.0 mg/mL, 100.0 mg, 10.0 mg/mL, 150.0 mg, 120.0 mg/mL, 395.0 mg, 388.0 mg/mL, 187.0 mg/mL, 388.0 mg, 25.0 mg/mL, 175.0 mg/mL, 60.0 mg/mL, 70.0 mg/mL, 90.0 mg/mL, 150.0 mg/mL, 75.0 mg/mL, 8.33 mg/mL, 380.0 mg, 390.0 mg, 125.0 mg/mL, 88.0 mg/mL, 1200.0 mg, 30.0 mg/mL, 375.0 mg, 35.0 mg, 2.0 mg/mL, 240.0 mg, 120.0 mg, 50.0 mg, 24.99 mg, 385.0 mg, 198.0 mg, 190.0 mg, 835.0 mg, 800.0 mg, 350.0 mg, 550.0 mg, 288.0 mg, 775.0 mg, 580.0 mg, 180.0 mg, 78.0 mg/mL, 780.0 mg, 1000.0 mg, 575.0 mg, 315.0 mg, 1100.0 mg, 650.0 mg, 15.0 mg/mL, 275.0 mg, 300.0 mg, 360.0 mg, 211.0 mg/mL, 35.0 mg/mL, 80.0 mg/mL, 4.2 mg/mL, 0.2 mg, 41.6 mg, 0.007 mg/mg, 0.21 mg/mg, 20.84 mg, 39.6 mg/mL, 0.4 mg/mg, 25.0 mg, 4.0 mg/mL, 37.5 mg/mL, 5.0 mg/mL, 22.1 mg/mL, 10000.0 mg/mL

, Liquid, Liquid - Oral, Solution, Oral, Solution - Oral, Powder, for solution, Powder, for solution - Oral, Syrup, Syrup - Oral, Tablet, coated, Tablet, film coated - Oral, Suspension, Suspension - Oral, Tablet, extended release, Tablet, film coated, Tablet, extended release - Oral, Tablet, coated - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Kit, Tablet, Tablet - Oral, Solution / drops, Capsule, coated - Oral, Capsule, coated, Capsule, Capsule - Oral, Suspension / drops, Capsule, gelatin coated - Oral, Capsule, gelatin coated, Solution / drops - Oral, Suspension / drops - Oral, Solution / drops - Nasal, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Granule - Oral, Granule, Elixir - Oral, Nasal, Elixir, Suppository - Rectal, Suppository, Kit; Tablet, Kit; Tablet - Oral, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Rectal, Capsule; Kit - Oral, Capsule; Kit, Kit - Oral, Tablet, multilayer, Tablet, multilayer - Oral, Gel - Oral, Gel, Nasal; Oral, Powder, Powder - Oral, Cream; Kit; Liquid; Ointment; Tablet; Tablet, chewable; Tablet, film coated - Oral; Topical, Oral; Topical, Cream; Kit; Liquid; Ointment; Tablet; Tablet, chewable; Tablet, film coated

Common Cold

Whooping Cough

House dust allergy

Hives

Acute Bronchitis

Exanthema

Bronchial Spasm

Rhinitis, Allergic

Productive cough

Coughing

Rhinorrhea

Fever

Influenza

Chronic Obstructive Pulmonary Disease

Tobacco Use

Pharyngitis

Bronchitis, Chronic

Food Hypersensitivity

Asthma

Warnings

Ovide Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Guaifenesin may interact with Pulse Frequency

Common Ovide Drug Interactions

Drug Name

Risk Level

Description

Ovide Toxicity & Overdose Risk

The lowest toxic dose of this drug in rats is 5628mg/kg. Overdosing can lead to nausea, vomiting, impaired central nervous system function, difficulty breathing, or even death. Long-term use of this drug can result in serious health problems such as liver and brain damage.

image of a doctor in a lab doing drug, clinical research

Ovide Novel Uses: Which Conditions Have a Clinical Trial Featuring Ovide?

32 active trials are presently investigating the potential of Ovide to manage Obstructive Hypertrophic Cardiomyopathy, Urinary Tract Infection (UTI) and Disinfection.

Condition

Clinical Trials

Trial Phases

Tracheitis

0 Actively Recruiting

Fever

2 Actively Recruiting

Not Applicable, Phase 4

Asthma

92 Actively Recruiting

Phase 1, Phase 4, Early Phase 1, Phase 2, Not Applicable, Phase 3

Chronic Obstructive Pulmonary Disease

76 Actively Recruiting

Phase 3, Phase 1, Phase 2, Not Applicable, Early Phase 1, Phase 4

Coughing

0 Actively Recruiting

chills occurring with fever

0 Actively Recruiting

Influenza

29 Actively Recruiting

Not Applicable, Phase 4, Phase 2, Phase 1, Phase 3

Tobacco Use

0 Actively Recruiting

Nasal Congestion

0 Actively Recruiting

Rhinitis, Allergic

0 Actively Recruiting

Pain

0 Actively Recruiting

Coughing

0 Actively Recruiting

excess mucus or phlegm

0 Actively Recruiting

Coughing

0 Actively Recruiting

Laryngitis

0 Actively Recruiting

Whooping Cough

0 Actively Recruiting

Exanthema

0 Actively Recruiting

Coughing

0 Actively Recruiting

Emphysema

4 Actively Recruiting

Phase 2, Not Applicable

Acute Bronchitis

1 Actively Recruiting

Not Applicable

Ovide Reviews: What are patients saying about Ovide?

Patient Review

12/14/2008

Ovide for Presence of Head Lice

I've tried many over-the-counter lice treatments with no success, but this medicine really does the trick. I have four kids who seem to bring home lice a few times a year, but since using this product we haven't had any problems for two years now.

Patient Review

10/18/2016

Ovide for Presence of Head Lice

This is the only medication that I've found to be effective at kill both lice and their eggs. I've used it twice now with great results. Anything else, like over-the-counter NIX, doesn't work. Ovide may smell bad but it's worth it!

3.7

Patient Review

3/25/2008

Ovide for Presence of Head Lice

My daughter was really struggling with head lice that weren't responding to over the counter treatments. We tried this as a last resort and it worked like a charm! The smell is pretty bad, but it did the job in one application and we haven't had any problems since.

Patient Review

3/15/2010

Ovide for Osteoporosis

This treatment is great. I love how it helps me feel better.

Patient Review

2/14/2010

Ovide for Presence of Head Lice

We've been dealing with head lice for over half a year now, and nothing we've tried has worked. We even got a prescription from a dermatologist, but it didn't do anything. Are there any other options out there?

1.7

Patient Review

3/7/2008

Ovide for Presence of Head Lice

We tried this as a last resort after our doctor recommended it, but it didn't work. We still have lice and now my hair is falling out on top of everything else. The side effects are also really terrible.

1.7

Patient Review

9/8/2008

Ovide for Presence of Head Lice

I've been struggling to get rid of head lice in my home for the last six months. I've tried over-the-counter treatments, products I found online, and finally had to beg my pediatrician for a prescription. I've used Ovide twice on everyone in my family, and both times we've ended up finding nits again. I wash all our bedding and clothes regularly, boil our brushes--I'm at wit's end. This has cost me so much money and time, and we still can't get rid of them!

image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about ovide

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is Ovide used for?

"Malathion (Ovide* lotion) is a prescription drug approved by the U.S. Food and Drug Administration (FDA) for the treatment of head lice infestation. The malathion lotion approved in the United States for the treatment of head lice is safe and effective when used as directed. If you have any questions about using this medication, ask your doctor or pharmacist."

Answered by AI

What is Ovide lotion?

"Malathion is a medication used to treat head lice, tiny insects that infest and irritate your scalp. Malathion works by paralyzing and killing lice and their eggs (nits)."

Answered by AI

How do you use Ovide lotion?

"To use Ovide Lotion, apply it to DRY hair in an amount that will thoroughly wet the hair and scalp. Be sure to focus on the back of the head and neck while applying Ovide Lotion. After applying the lotion to your scalp, wash your hands. Allow your hair to air dry naturally - do not use any electric heat source, and allow your hair to remain uncovered."

Answered by AI

Does malathion have side effects?

"Serious health effects from short-term exposure to high levels of malathion are rare, but can include seizures, unconsciousness, and death.

Exposure to high levels of malathion can cause a variety of symptoms affecting the nervous system, including headaches, nausea, dizziness, weakness, cramps, diarrhea, excessive sweating, and blurred vision. In rare cases, exposure to high levels of malathion can cause serious health effects, such as seizures, unconsciousness, and death."

Answered by AI

Clinical Trials for Ovide

Have you considered Ovide clinical trials?

We made a collection of clinical trials featuring Ovide, we think they might fit your search criteria.

Image of Stanford University in Stanford, United States.

MoblO2 for Chronic Lung Diseases

18+

All Sexes

Stanford, CA

Many patients with chronic lung disease (e.g., chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD)) require supplemental oxygen (O2) at some point during their disease course. Practitioners prescribe O2 to patients with chronic lung disease in hopes of the following: 1) that it will limit desaturation events and combat breathlessness, thus preventing the frustratingly slow pace and numerous rest breaks patients are forced to adopt while doing even simple tasks; 2) that it will allow patients to be more active physically (perhaps increase their ability to exercise) and socially (perhaps leave the home more often); 3) that it will stave off putative complications of hypoxemia (e.g., cognitive dysfunction, pulmonary hypertension) and 4) that it will improve health-related quality of life (HRQL). However, despite the rationale for O2, and prescribers' good intentions, patients generally view O2 with frustration and fear - it threatens their HRQL, which is already impaired by having a condition that imposes itself on every aspect of their lives. Nasal cannulas and delivery devices call unwanted attention to patients when they are out in public. O2 users feel stigmatized and are often viewed as "smokers who get what they deserve, even if they never smoked a day in their lives" - or as disabled, sick or even infectious. O2 steals patients' independence, forcing them to plan their lives around it. The anxiety that patients and their caregivers experience around running out of oxygen, or not getting enough, immobilizes them and restricts participation in activities outside of the home. O2 disrupts the home environment, adding stress, and creating a burden for patients' caregiver-loved-ones who are often saddled with the responsibility of ensuring adequate equipment and supply of O2, and O2 is a constant reminder to patients they are living with a condition that could shorten their lives. O2 delivery equipment is typically heavy, unwieldy and intimidating. Different recommendations (e.g., insurance companies use 88% as a cut-off for SpO2, while many practitioners focus on 90%) make it confusing for patients, which almost certainly affects adherence. O2-requiringpatients are starving for things that can make their lives easier. An auto-adjusting O2 delivery device - one that automatically delivers the correct amount of O2 to maintain blood oxygen at desired, pre-set levels - would alleviate the need for patients to constantly (incessantly for many) monitor their peripheral oxygen saturation (SpO2) and adjust O2flow to meet the demands as exertion levels vary . The MoblO2 device is a battery-operated, light-weight, closed-loop O2 delivery device that houses a regulator (which attaches to compressed gas O2 tanks) and adjusts O2 flow to meet a pre-set blood oxygen level. A pulse oximeter is worn on the ear and transmits via Bluetooth to the device, which adjusts an internal valve to control flow on a second-to-second basis. The user sets the dial to the highest flow of O2 needed to meet the demands of activities they might perform (up to 15 liters per minute), and the device adjusts flow, up to the pre-set level to maintain SpO2 at a preset level (e.g., \> 90%). To conserve O2 supply in the tank - and to avoid over-oxygenation (which could be problematic for a small percentage of patients with the most severe COPD) - the MoblO2 begins to limit O2 flow at a SpO2 of 93%. The device can be manually over-ridden by the user, and should the battery run out - or the device fail for some unforeseen reason - the default position is valve open, so the users receive whatever flow of oxygen has been set on the dial. Given the substantial burdens of O2 on patients and their families, the hassles patients describe with having to monitor their SpO2 and repeatedly adjust the flow of O2 to meet their needs, patients and experts around the world have called for improvements in O2 delivery equipment. The MoblO2 is just such a remarkable improvement and a giant step forward in helping to ease the burdens of O2 on patients who require it. The purpose of this study is to investigate the effects of the MoblO2 O2 delivery device on a range of outcomes, including physical activity, amount (liters) O2 use; maintenance of adequate SpO2 levels; patient reported outcomes including symptoms, HRQL and satisfaction with the MoblO2 O2 device.

Waitlist Available

Has No Placebo

Stanford University

Jeff Swigris, DO, MS

Minnesota Health Solutions

Have you considered Ovide clinical trials?

We made a collection of clinical trials featuring Ovide, we think they might fit your search criteria.

Image of Vanderbilt University Medical Center in Nashville, United States.

High vs. Standard Dose Influenza Vaccines for Flu

18+

All Sexes

Nashville, TN

This will be a follow-up study to the "Comparison of High Dose vs. Standard Dose Influenza Vaccine in Lung Allograft Recipient" study (DMID Protocol Number 22-0014) at Vanderbilt University Medical Center. Lung transplantation is a life-saving therapy for patients with advanced lung disease, and is also associated with an improvement in quality of life. However, due to the need for life-long immunosuppression to prevent acute cellular rejection and chronic lung allograft dysfunction ("chronic rejection"), lung transplant recipients are at risk for developing major infections. In fact, one-year survival is 85%, with infection being the leading cause of death within the first year post-transplant. We will conduct a follow-up phase II, randomized, double-blind trial to assess the impact of subsequent administration of two doses of HD-IIV compared to two doses of SD-IIV among lung recipients during the early post-transplant period. Demonstration of improved immunogenicity from two doses of HD-IIV over consecutive influenza seasons would provide potential broad benefit in reducing influenza disease and its associated complications in lung transplant recipients. Moreover, studying vaccine immunogenicity and safety in the same participants over consecutive years can provide insight into the influence of immunosuppression levels and allograft aging on vaccine-mediated immune modulation. This proposed study design will contribute significantly to influenza vaccination guidance and policy for the highly vulnerable lung transplant population. This proposed study is designed to address several key knowledge gaps in vaccine-mediated protection of lung transplant recipients against influenza: * Is there increased immunogenicity with administration of one or two doses of HD-IIV or SD-IIV in the subsequent season compared to two doses of HD-IIV or SD-IIV in the first season? * What is the durability of the humoral and cellular immune response between influenza seasons and does two doses of HD-IIV or SD-IIV sustain higher HAI titers compared to two doses of HD-IIV or SD-IIV in the first season? * What is the impact of maintenance immunosuppression levels on influenza vaccine immunogenicity within the same participant? * Will the optimal immunogenic vaccination strategy be associated with an acceptable long-term safety profile over successive influenza seasons, including injection-site and systemic reactions, allosensitization, and organ rejection?

Phase 2

Recruiting

Has No Placebo

Vanderbilt University Medical Center

Natahsa Halasa, MD, MPH